N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof

A compound of Formula I, a stereoisomer, a tautomer, a geometric isomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof,

• wherein,
• X and Y each independently represent CR7, and said R7 is independently selected from the group consisting of hydrogen, C3-4 cycloalkyl, —CN, fluoro, chloro, bromo and C1-3 alkyl, wherein said C1-3 alkyl is optionally substituted with one or more fluoro;
• ring A is selected from the group consisting of phenyl and 5- to 10-membered heteroaryl;
• R1, R2 and R3 are each independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, —CHF2, —CH2F, —CF3, —CN, C1-3 alkyl, and C3-4 cycloalkyl;
• R4 is selected from the group consisting of hydrogen, C1-3 alkyl and C3-4 cycloalkyl;
• R5 is selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 3- to 7-membered cycloalkyl and 3- to 7-membered heterocycloalkyl, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 3- to 7-membered cycloalkyl and 3- to 7-membered heterocycloalkyl are optionally substituted with the group(s) selected from the group consisting of halo, 3- to 4-membered cycloalkyl, 3- to 4-membered heterocycloalkyl, —OR8, oxo, —CN, —C(O)OR8, —SO2R8, —C(O)N(R8)2, and C1-3 alkyl, wherein C1-3 alkyl is optionally substituted with one or more groups selected from the group consisting of fluoro, —CN and —OH;
• and
• each R8 is independently selected from the group consisting of hydrogen and C1-3 alkyl.